Male infertility accounts for nearly half of India's 27 million cases, say experts
'Behind the market expansion are millions of emotionally taxing, often invisible journeys. Nearly half of these involve male-factor infertility, but men remain largely absent from the conversation,' Dr Patki said at the just-concluded summit, which was hosted by the Integrated Health & Wellbeing (IHW) Council in collaboration with the Indian Society for Assisted Reproduction (ISAR) and supported by the Indian Fertility Society (IFS).
This exclusion has real-world consequences: delays in diagnosis, gendered treatment approaches, and emotional distress for couples navigating the healthcare system.
According to Kamal Narayan, CEO of the IHW Council, 'Male infertility is no longer a fringe issue, it is a national health priority. We cannot talk about inclusive fertility care without addressing this reality head-on.'
The summit brought together clinicians, embryologists, hospital leaders, legal experts, and patient advocates in a bid to realign India's fertility care narrative.
One notable moment came with the launch of the book How to Freeze Your Biological Clock by Dr. Gunjan Gupta, Medical Director of Gunjan IVF World. Though primarily aimed at guiding women through fertility preservation, the book also contributes to the broader conversation around evidence-based and gender-inclusive fertility planning.
The message from experts is clear: India's fertility ecosystem must move beyond stigma and adopt a scientifically grounded, emotionally attuned approach that acknowledges infertility as a shared burden. And male reproductive health as a critical part of the solution.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
4 hours ago
- Mint
Jiangsu Hengrui Pharma stock spikes 10% to 4-year high on drug development deal with GSK – here's what the company does
Shares of Jiangsu Hengrui Pharmaceuticals Company, a Chinese pharmaceutical firm, jumped 10% to hit a 4-year high of 61-yuan, equivalent to USD 9.62 on the Shanghai Stock Exchange (SSE), after the company announced that it had agreed to license the global rights of its HRS-9821 drug and 11 other programs to GlaxoSmithKline Intellectual Property (GSK). The programs were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I), and Oncology pipeline, having been assessed for their potential best-in-class or first-in-class profiles. The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong, Macau, and Taiwan) for a potential best-in-class PDE3/4 inhibitor (HRS-9821), which is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, regardless of background therapy, GSK said in its filing on Monday. The British pharmaceutical giant added that HRS-9821 supports its ambition to treat patients across the widest spectrum of COPD, including those who experience continued dyspnea (shortness of breath) or are unlikely to receive inhaled corticosteroids or biologics, based on their disease profile. The agreements also feature a pioneering, large-scale collaboration to develop up to 11 additional programs besides HRS-9821, each with its own financial structure. Hengrui Pharma will lead the development of these programs up to the completion of Phase I trials, including trials involving patients outside of China. GSK will have the exclusive option to further develop and commercialize each program worldwide (excluding mainland China, Hong Kong, Macau, and Taiwan) at the end of Phase I or earlier, at its discretion, and will also have program substitution rights. GSK has agreed to pay $500 million in upfront fees across the agreements, including for the license of the PDE3/4 program. The potential total value of future success-based development, regulatory, and commercial milestone payments to Hengrui Pharma could reach approximately $12 billion if all programs are optioned and all milestones are met. Additionally, Hengrui Pharma will be eligible for tiered royalties on global product net sales (excluding mainland China, Hong Kong, Macau, and Taiwan). The license to HRS-9821 remains subject to customary conditions, including regulatory clearance under the Hart-Scott-Rodino Act in the United States. Tony Wood, Chief Scientific Officer at GSK, said, 'We're delighted to announce these exciting agreements with Hengrui Pharma, which complement our already extensive pipeline. This deal reflects our strategic investment in programs that address validated targets, increasing the likelihood of success, while giving us the option to advance the assets with the greatest potential for patient impact.' Founded in 1970, Hengrui Pharma is a global pharmaceutical company dedicated to research, development, and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D network of 14 centers and over 5,500 professionals, Hengrui's therapeutic focus includes oncology, metabolic and cardiovascular diseases, immunological and respiratory disorders, and neuroscience. To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
Mint
9 hours ago
- Mint
NRIs turning to India for high-quality quality affordable healthcare, customers up 150% YoY in FY25: Report
New Delhi [India], July 28 (ANI): Non-Resident Indians (NRIs) are increasingly choosing India as their destination for high-quality and affordable healthcare, according to the data released by Policybazaar. The data showed a significant 150 per cent growth in the share of NRI customers in FY 2024-25 compared to FY 2023-24, highlighting India's growing appeal in the global medical tourism space. It stated, "India is fast emerging as one of the world's most sought-after medical tourism hubs. The growth is quite visible with more NRIs turning to India to access high-quality healthcare. Our data indicates a 150 per cent overall growth in the share of NRI customers in FY 25". One of the key reasons behind this mentioned in the data report is the surge is the massive cost advantage India offers for medical treatments when compared to countries like the United States and the United Kingdom. For instance, heart bypass surgery in India costs between USD 5,000 and USD 8,000, while the same procedure in the U.S. can cost between USD 70,000 and USD 150,000. Similarly, a knee replacement surgery costs only USD 4,000 to USD 6,000 in India, compared to USD 30,000 to USD 50,000 in the U.S. A liver transplant in India is priced between USD 25,000 and USD 35,000, whereas it costs USD 300,000 to USD 500,000 in the U.S. NRIs opting for elective procedures in India typically have average claim amounts ranging from USD 2,000 to USD 15,000. For more complex surgeries, the claims may rise to USD 20,000 to USD 40,000, still representing considerable savings when compared to international healthcare costs. The affordability factor also extends to health insurance premiums. In India, the average annual health insurance premium per person ranges from USD 120 to USD 300. In contrast, the same coverage in the U.S. can exceed USD 8,000 annually, while in GCC countries, it ranges from USD 4,000 to USD 5,000. This significant difference has led to a visible increase in online searches by NRIs exploring health insurance options in India for themselves and their families. The data further reveals a 125 per cent surge in the share of women NRI customers and a 148 per cent increase in the number of NRI customers under the age of 35. This showed that younger NRIs and women are increasingly considering Indian healthcare as a preferred choice. When it comes to preferred locations for treatment, South Indian cities continue to dominate the list across all tiers. Cities like Mumbai, Kolkata, Pune, and Thane are also gaining popularity among NRI patients. With a combination of quality care, advanced medical infrastructure, and substantial cost benefits, India is rapidly emerging as a leading hub for NRI medical needs. (ANI)
New Indian Express
2 days ago
- New Indian Express
Male infertility accounts for nearly half of India's 27 million cases, say experts
Dr. Ameet Patki, President of ISAR, warned that while India's IVF market is projected to soar, from USD 750 million in 2020 to a staggering USD 3.7 billion by 2030 those figures represent more than just business growth. 'Behind the market expansion are millions of emotionally taxing, often invisible journeys. Nearly half of these involve male-factor infertility, but men remain largely absent from the conversation,' Dr Patki said at the just-concluded summit, which was hosted by the Integrated Health & Wellbeing (IHW) Council in collaboration with the Indian Society for Assisted Reproduction (ISAR) and supported by the Indian Fertility Society (IFS). This exclusion has real-world consequences: delays in diagnosis, gendered treatment approaches, and emotional distress for couples navigating the healthcare system. According to Kamal Narayan, CEO of the IHW Council, 'Male infertility is no longer a fringe issue, it is a national health priority. We cannot talk about inclusive fertility care without addressing this reality head-on.' The summit brought together clinicians, embryologists, hospital leaders, legal experts, and patient advocates in a bid to realign India's fertility care narrative. One notable moment came with the launch of the book How to Freeze Your Biological Clock by Dr. Gunjan Gupta, Medical Director of Gunjan IVF World. Though primarily aimed at guiding women through fertility preservation, the book also contributes to the broader conversation around evidence-based and gender-inclusive fertility planning. The message from experts is clear: India's fertility ecosystem must move beyond stigma and adopt a scientifically grounded, emotionally attuned approach that acknowledges infertility as a shared burden. And male reproductive health as a critical part of the solution.
